Sr89 chloride is primarily used to treat which condition?

Sr89 chloride is primarily used to treat which condition?

• A. Bone cancer
• B. Bone pain
• C. Rheumatoid arthritis
• D. Malignant effusions

Answer: (B)

Strontium-89 chloride is primarily utilized in the management of bone pain, particularly pain resulting from metastatic bone disease. The isotope mimics calcium and preferentially accumulates in areas of increased bone turnover, such as those affected by metastases. In the treatment protocol, Sr-89 delivers beta radiation directly to the bone metastases, which helps alleviate pain associated with these conditions. Patients suffering from cancers such as prostate or breast cancer that have spread to the bones often experience significant discomfort that can severely impact their quality of life. While bone cancer is indeed a condition that may involve the use of radiopharmaceuticals, the direct and specific application of Sr-89 is focused on alleviating the pain caused by metastatic lesions rather than treating the bone cancer itself. Additionally, conditions like rheumatoid arthritis and malignant effusions are not the intended targets for treatment with Sr-89, as their underlying pathophysiology and treatment strategies differ significantly from the management of cancer-related bone pain.

Strontium-89 chloride is primarily utilized in the management of bone pain, particularly pain resulting from metastatic bone disease. The isotope mimics calcium and preferentially accumulates in areas of increased bone turnover, such as those affected by metastases.

In the treatment protocol, Sr-89 delivers beta radiation directly to the bone metastases, which helps alleviate pain associated with these conditions. Patients suffering from cancers such as prostate or breast cancer that have spread to the bones often experience significant discomfort that can severely impact their quality of life.

While bone cancer is indeed a condition that may involve the use of radiopharmaceuticals, the direct and specific application of Sr-89 is focused on alleviating the pain caused by metastatic lesions rather than treating the bone cancer itself. Additionally, conditions like rheumatoid arthritis and malignant effusions are not the intended targets for treatment with Sr-89, as their underlying pathophysiology and treatment strategies differ significantly from the management of cancer-related bone pain.